Skip to main content
Wanbury Limited logo

Wanbury Limited — Investor Relations & Filings

Ticker · WANBURY ISIN · INE107F01022 LEI · 335800QB384KGMBID276 BSE.NS Manufacturing
Filings indexed 916 across all filing types
Latest filing 2024-05-09 Regulatory Filings
Country IN India
Listing BSE.NS WANBURY

About Wanbury Limited

https://www.wanbury.com

Wanbury Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization maintains a significant global presence, particularly as a leading producer of Metformin. Its product portfolio spans diverse therapeutic areas, including gynecology, orthopedics, hematinics, and anti-diabetics. The company operates manufacturing facilities compliant with international regulatory standards, including the USFDA. Wanbury focuses on providing medicinal solutions through integrated research and development capabilities and large-scale production infrastructure, serving both domestic and international markets with a range of specialty products.

Recent filings

Filing Released Lang Actions
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 95% confidence The document text is extremely short (817 characters) and consists solely of digital signature information without any substantive content related to financial reports, management changes, or announcements. There is no mention of any report, meeting, financial data, or regulatory filing content. Given the lack of any report or announcement content and the presence of only digital signature metadata, this document does not fit into any specific report category. According to the rules, such documents fall under the fallback category of Regulatory Filings (RNS).
2024-05-09 English
Board Meeting — WANBURY LIMITED has informed the Exchange about Board Meeting to be held on 16-May-2024 to inter-alia consider and approve the Audited Financial results of the Company for the Yearly…
Regulatory Filings
2024-05-07 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document text is extremely short (592 characters) and contains only a digital signature block with no substantive content related to financial reports, announcements, or filings. There is no mention of any report type, regulatory body, fiscal period, or financial data. Given the lack of content and the presence of a digital signature, this document does not fit into any specific report category and is best classified as a Regulatory Filing (RNS), which serves as a fallback category for miscellaneous filings that do not fit elsewhere.
2024-05-07 English
WANBURY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2024 ,inter alia, to consider and approve Notice is hereby given pursuant to ....
Regulatory Filings
2024-05-07 English
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details ....
Regulatory Filings
2024-04-30 English
Certificate under Regulation 40(9) for the year ended on 31st March,2024.
Regulatory Filings
2024-04-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.